9.10
Schlusskurs vom Vortag:
$8.125
Offen:
$8.12
24-Stunden-Volumen:
54,291
Relative Volume:
1.75
Marktkapitalisierung:
$19.59M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-563.30K
KGV:
-45.59
EPS:
-0.1996
Netto-Cashflow:
$-22.23M
1W Leistung:
+23.64%
1M Leistung:
-6.35%
6M Leistung:
-28.51%
1J Leistung:
-63.96%
Promis Neurosciences Inc Stock (PMN) Company Profile
Firmenname
Promis Neurosciences Inc
Sektor
Branche
Telefon
416-847-6898
Adresse
SUITE 200, 1920 YONGE STREET, TORONTO
Vergleichen Sie PMN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
PMN
Promis Neurosciences Inc
|
9.10 | 17.49M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Promis Neurosciences Inc Aktie (PMN) Neueste Nachrichten
ProMIS Neurosciences (PMN) Reveals Promising Study Results for A - GuruFocus
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - GlobeNewswire
Pretax income of ProMIS Neurosciences Inc. – BER:23J - TradingView
ProMIS Neurosciences (PMN) Price Target Increased by 2,288.89% to 137.06 - Nasdaq
Can ProMIS Neurosciences Inc. (23J0) stock sustain margin levelsJuly 2025 Closing Moves & Weekly Top Gainers Alerts - Newser
HC Wainwright Has Strong Forecast for PMN FY2025 Earnings - Defense World
How strong is ProMIS Neurosciences Inc. (23J0) stock earnings growth2025 Institutional Moves & Weekly Breakout Watchlists - Newser
How geopolitical risks impact ProMIS Neurosciences Inc. (23J0) stock2025 Market Trends & Long-Term Growth Stock Strategies - Newser
ProMIS Neurosciences announces publication on plasma pTau in Alzheimer’s - MSN
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
Why hedge funds are buying ProMIS Neurosciences Inc. stockWeekly Trade Recap & AI Based Buy/Sell Signal Reports - Newser
symbol__ Stock Quote Price and Forecast - CNN
HC Wainwright & Co. Maintains ProMIS Neurosciences (PMN) Buy Recommendation - Nasdaq
ProMIS Neurosciences Inc (23J0.DU) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
PMN: HC Wainwright & Co. Raises Price Target and Maintains Buy R - GuruFocus
ProMIS Neurosciences stock rises after promising Alzheimer’s research data By Investing.com - Investing.com Nigeria
ProMIS Neurosciences (PMN) Sees Revised Price Target from H.C. W - GuruFocus
ProMIS Neurosciences stock rises after promising Alzheimer’s research data - Investing.com
ProMIS Neurosciences (PMN) Presents Key Insights in Alzheimer's Research - GuruFocus
Plasma pTau identified as key early endpoint in Alzheimer's research - marketscreener.com
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - Sahm
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - marketscreener.com
ProMIS Neurosciences Inc. Financial Statements – TRADEGATE:23J - TradingView
EBITDA of ProMIS Neurosciences Inc. – TRADEGATE:23J - TradingView
ProMIS Neurosciences Inc. Financial Disclosures & Filings - TradingView
Diluted net income available to common stockholders of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Net margin % of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Net income before discontinued operations of ProMIS Neurosciences Inc. – FWB:23J - TradingView
Total common shares outstanding of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Enterprise value of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Promis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Price to cash flow ratio of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Tangible book value per share of PROMIS NEUROSCIENCES – FWB:23J - TradingView
ProMIS Neurosciences (STU:23J) Beneish M-Score : 0.00 (As of Nov. 30, 2025) - GuruFocus
ProMIS Neurosciences (STU:23J) Gross Margin % : 0.00% (As of Sep. 2025) - GuruFocus
ProMIS Neurosciences (STU:23J) Other Financing : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
ProMIS Neurosciences Inc (STU:23J) Stock Price & 30 Year Financial Data - GuruFocus
ProMIS Neurosciences (STU:23J) Dividends per Share : €0.00 (TTM As of Sep. 2025) - GuruFocus
ProMIS Neurosciences Inc (STU:23J) Stock Earnings Transcripts - GuruFocus
ProMIS Neurosciences (STU:23J) Construction In Progress : €0.00 Mil (As of Sep. 2025) - GuruFocus
Revenue per share of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Free cash flow per share of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Return on assets % of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Long term debt to total equity ratio of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Asset turnover of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Operating cash flow per share of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Return on invested capital % of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Debt to assets ratio of PROMIS NEUROSCIENCES – FWB:23J - TradingView
ProMIS Neurosciences (FRA:23J) Change In Working Capital : €4.99 Mil (TTM As of Sep. 2025) - GuruFocus
Working capital per share of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Finanzdaten der Promis Neurosciences Inc-Aktie (PMN)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):